Phimosis: A rare complication of immunotherapy with durvalumab

We present a case of a 69 year old man with phimosis associated with immunotherapy with durvalumab for metastatic non-small-cell lung cancer. The patient developed vitiligo like dermatosis after the induction dose of durvalumab, subsequent administration of the immunotherapy the patient developed a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vázquez-Lavista, Luis Gabriel, Llorente, Luis, Alatorre-Alexander, Jorge, Ramírez-Muciño, José Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573967/
https://www.ncbi.nlm.nih.gov/pubmed/33102050
http://dx.doi.org/10.1016/j.eucr.2020.101350
_version_ 1783597544010416128
author Vázquez-Lavista, Luis Gabriel
Llorente, Luis
Alatorre-Alexander, Jorge
Ramírez-Muciño, José Arturo
author_facet Vázquez-Lavista, Luis Gabriel
Llorente, Luis
Alatorre-Alexander, Jorge
Ramírez-Muciño, José Arturo
author_sort Vázquez-Lavista, Luis Gabriel
collection PubMed
description We present a case of a 69 year old man with phimosis associated with immunotherapy with durvalumab for metastatic non-small-cell lung cancer. The patient developed vitiligo like dermatosis after the induction dose of durvalumab, subsequent administration of the immunotherapy the patient developed a fibrous ring of the foreskin. Immune-mediated adverse reactions have been described after the use of durvalumab, but, to our knowledge, there are no reports of phimosis and vitiligo like reactions.
format Online
Article
Text
id pubmed-7573967
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75739672020-10-23 Phimosis: A rare complication of immunotherapy with durvalumab Vázquez-Lavista, Luis Gabriel Llorente, Luis Alatorre-Alexander, Jorge Ramírez-Muciño, José Arturo Urol Case Rep Oncology We present a case of a 69 year old man with phimosis associated with immunotherapy with durvalumab for metastatic non-small-cell lung cancer. The patient developed vitiligo like dermatosis after the induction dose of durvalumab, subsequent administration of the immunotherapy the patient developed a fibrous ring of the foreskin. Immune-mediated adverse reactions have been described after the use of durvalumab, but, to our knowledge, there are no reports of phimosis and vitiligo like reactions. Elsevier 2020-07-16 /pmc/articles/PMC7573967/ /pubmed/33102050 http://dx.doi.org/10.1016/j.eucr.2020.101350 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Oncology
Vázquez-Lavista, Luis Gabriel
Llorente, Luis
Alatorre-Alexander, Jorge
Ramírez-Muciño, José Arturo
Phimosis: A rare complication of immunotherapy with durvalumab
title Phimosis: A rare complication of immunotherapy with durvalumab
title_full Phimosis: A rare complication of immunotherapy with durvalumab
title_fullStr Phimosis: A rare complication of immunotherapy with durvalumab
title_full_unstemmed Phimosis: A rare complication of immunotherapy with durvalumab
title_short Phimosis: A rare complication of immunotherapy with durvalumab
title_sort phimosis: a rare complication of immunotherapy with durvalumab
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573967/
https://www.ncbi.nlm.nih.gov/pubmed/33102050
http://dx.doi.org/10.1016/j.eucr.2020.101350
work_keys_str_mv AT vazquezlavistaluisgabriel phimosisararecomplicationofimmunotherapywithdurvalumab
AT llorenteluis phimosisararecomplicationofimmunotherapywithdurvalumab
AT alatorrealexanderjorge phimosisararecomplicationofimmunotherapywithdurvalumab
AT ramirezmucinojosearturo phimosisararecomplicationofimmunotherapywithdurvalumab

Ejemplares similares